Astrazeneca plc ADR [NASDAQ: AZN] slipped around -0.9 points on Tuesday, while shares priced at $72.60 at the close of the session, down -1.22%.
Compared to the average trading volume of 5.51M shares, AZN reached a trading volume of 3250885 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Astrazeneca plc ADR [AZN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $89.01 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.42. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Astrazeneca plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 13, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on February 12, 2025, representing the official price target for Astrazeneca plc ADR stock.
The Average True Range (ATR) for Astrazeneca plc ADR is set at 1.30, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.16. The Price to Book ratio for the last quarter was 5.52, with the Price to Cash per share for the same quarter was set at 1.82. Price to Free Cash Flow for AZN in the course of the last twelve months was 21.90 with Quick ratio for the last quarter at 0.74.
How has AZN stock performed recently?
Astrazeneca plc ADR [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.62. With this latest performance, AZN shares dropped by -4.60% in over the last four-week period, additionally sinking by -6.47% over the last 6 months – not to mention a rise of 7.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 40.22, with the RSI for the last a single of trading hit 33.78, and the three-weeks RSI is set at 44.97 for Astrazeneca plc ADR [AZN]. The present Moving Average for the last 50 days of trading for this stock 73.67, while it was recorded at 73.09 for the last single week of trading, and 74.64 for the last 200 days.
Astrazeneca plc ADR [AZN]: Deeper insight into the fundamentals
Astrazeneca plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.74 and a Current Ratio set at 0.93.
Earnings analysis for Astrazeneca plc ADR [AZN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Astrazeneca plc ADR go to 10.85%.
Insider trade positions for Astrazeneca plc ADR [AZN]
There are presently around $17.49%, or 17.49%% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 64.94 million shares, which is approximately 4.1788%. PRIMECAP MANAGEMENT CO/CA/, holding 42.6 million shares of the stock with an approximate value of $$3.32 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $$3.16 billion in AZN stock with ownership which is approximately 2.6106%.
